Spectral AI

MDAI

Market cap $46M

DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the Southern Region Burn Conference, held from October 30th – November 2nd in Charleston, South Carolina. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the country.

Spectral AI, Inc. ( MDAI ) Q3 2025 Earnings Call November 11, 2025 5:00 PM EST Company Participants Sara Prendergast John DiMaio - Founder & Chairman Vincent Capone - CFO, General Counsel & Corporate Secretary Conference Call Participants Carl Byrnes - Northland Capital Markets, Research Division John Vandermosten - Zacks Small-Cap Research Presentation Operator Good day, and welcome to the Spectral AI Inc. Q3 2025 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025 Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continued to advance key regulatory and operational milestones, including progress toward its De Novo FDA submission.

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.

DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the pricing of a $7.6 million offering. The offering will provide the Company with additional growth capital for the continued expansion and development of its DeepView® System.

DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to TIME's World's Top HealthTech Companies 2025 list. The ranking, released September 18, 2025, can be viewed on Time.com.

DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the European Burns Association (EBA) conference, held from September 3rd – 6th in Berlin, Germany.

Spectral AI, Inc. (NASDAQ:MDAI ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Dr.Michael DiMaio - Chairman of the Board Sara Prendergast - Corporate Participant Assistant General Counsel - Corporate Participant Vincent Stanley Capone - CFO, General Counsel & Corporate Secretary Conference Call Participants Carl Edward Byrnes - Northland Capital Markets, Research Division John D. Vandermosten - Zacks Small-Cap Research Ryan Benjamin Zimmerman - BTIG, LLC, Research Division Operator Good afternoon, everyone, and welcome to the Spectral AI Inc. Q2 2025 Financial Results Conference Call.

Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 Million Strong Cash position of $10.5 Million Submission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2025 and provided an update on its ongoing business activities. “We are pleased with the results of our second quarter of 2025 especially with our ability to complete our submission of our De Novo application earlier than projected to the US Food and Drug Administration (“FDA”).

DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 12, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.